Development and evaluation of a generic physiologically based pharmacokinetic model for children.
about
Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically based toxicokinetic modelDevelopmental pharmacokinetics in pediatric populationsDevelopment of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primatesDietary Iodine Sufficiency and Moderate Insufficiency in the Lactating Mother and Nursing Infant: A Computational PerspectivePart 10: Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations.Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsReduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical DataChanges in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelChallenges in conducting clinical trials in children: approaches for improving performanceConcomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.The hypothalamic-pituitary-thyroid axis in infants and children: protection from radioiodinesTranslational learning from clinical studies predicts drug pharmacokinetics across patient populations.Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermiaPhysiologically based pharmacokinetic modeling and simulation in pediatric drug developmentPhysiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modellingClomipramine concentration and withdrawal symptoms in 10 neonates.Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics.Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.Pharmacokinetic studies in infants using minimal-risk study designsA detailed physiologically based model to simulate the pharmacokinetics and hormonal pharmacodynamics of enalapril on the circulating endocrine Renin-Angiotensin-aldosterone systemModeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.Whole-body physiologically based pharmacokinetic models.A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepamDose selection based on physiologically based pharmacokinetic (PBPK) approaches.Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in childrenDevelopment of a paediatric population-based model of the pharmacokinetics of rivaroxaban.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Physiologically based pharmacokinetics (PBPK).Pharmacokinetics in special populations.Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates.Knowledge-driven approaches for the guidance of first-in-children dosing.Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.An update on computational oral absorption simulation.Allometric extrapolation of factors VII, VIII and IX clearance in children from adults.Physiologically based pharmacokinetic (PBPK) modeling in children.Prediction of morphine clearance in the paediatric population : how accurate are the available pharmacokinetic models?
P2860
Q24647832-75EE5150-7527-4997-8129-5578EB64DA6CQ27002933-B571D8AB-032B-4A7B-A498-6D20AC6B5ED0Q28393582-6C19F65F-AADA-46C8-B4B5-69BEDA3A0429Q29109842-9AF3AA66-68C6-49BD-ABE0-3D6C23D41887Q30543305-8BB0C625-88A2-4379-80A3-E5E0ABB1E322Q30828459-26AE2B92-5759-475F-8A68-0E195B464011Q31018133-993B63F7-F70D-4236-8831-8DEC756B2113Q33574126-384E1702-ED82-48AD-A14C-13B8783A06F3Q33717140-10F27978-C0F1-4F0E-89BE-3DD346796C77Q33756964-0BFDCB76-B03B-4F32-A257-7FEE448B8F7EQ33757571-4C6CDC04-C5BA-49B9-A8D7-F44F508756A1Q33767468-761106B0-9307-4360-B1D2-A82BE4D5CADDQ34200271-0A437BFD-5B39-49C7-9768-9497875A2A9DQ34658074-38B92731-B06A-412C-AB92-59926CE3EDA0Q35054518-F169BE2D-66CB-4C92-8025-90328536B389Q35718576-34949D32-3E4C-4608-9E09-A1D1B9C94D8EQ35718651-85CD5EDD-175C-4A7C-8098-D9F144DF6142Q36057407-B92ABD95-3BAB-4C0E-B49F-AB7C2D1317CCQ36307045-AD8A1F79-EAAA-485A-9327-9E02A308A606Q36410220-64E249FF-29E0-4290-BDF1-15BD4781E501Q36438116-A98FA9B2-FAAF-4B73-82BB-2FF90A7B7733Q36595721-EB3D285E-4245-425B-A373-DE341FC335E9Q36702459-5950F65B-7E32-4EDE-A282-DF5BDEC1B8BDQ36788418-D55487E3-7CA2-48E4-B8B2-2C66B088AA87Q36910537-A4BF274F-9790-4DB1-8849-A9BD6D3EDA76Q36910606-611A1DEB-7998-4340-B40B-003C00745B81Q37008900-F01805AB-9A9D-487B-A72F-B49C151F1B6AQ37200292-D6B21574-94C4-4B13-B172-16A31D427FE3Q37279407-DF3FEB9B-B59B-4451-B6BE-329431017C4FQ37470692-2CEE6FAF-5671-446F-A77E-DD77CC2FDDEFQ37521422-DE304E32-621B-4907-B4EE-A1D265B8E090Q37550553-0A4F3EC3-D318-4043-82DC-D2D1F6A891C1Q37550561-E05DBCE8-BF84-4F8B-9CB6-5BE3FDA74BC3Q37694755-B0D87EFC-A18D-42CF-9C48-E2E9A76636A6Q37815555-21220E4D-7056-498C-82AA-29B82301C6A2Q37824590-2F532E26-1E6D-4BA9-B92F-8CC3CAF2C0FCQ37937047-E99CCBAD-205D-4521-A6DD-4C647787DB86Q38011809-8D140445-AAB4-4CD6-8C0F-C0E112FCFBF4Q38016332-061D379D-6E32-4381-8CE4-4E5C4982F24BQ38047202-DCA3B276-8F52-47F2-A8BA-599828A9DDCE
P2860
Development and evaluation of a generic physiologically based pharmacokinetic model for children.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Development and evaluation of ...... acokinetic model for children.
@en
Development and evaluation of ...... acokinetic model for children.
@nl
type
label
Development and evaluation of ...... acokinetic model for children.
@en
Development and evaluation of ...... acokinetic model for children.
@nl
prefLabel
Development and evaluation of ...... acokinetic model for children.
@en
Development and evaluation of ...... acokinetic model for children.
@nl
P2860
P1476
Development and evaluation of ...... acokinetic model for children.
@en
P2093
Andrea N Edginton
Stefan Willmann
P2860
P304
P356
10.2165/00003088-200645100-00005
P577
2006-01-01T00:00:00Z
P6179
1037331185